HK1222647A1 - 激酶抑制劑 - Google Patents

激酶抑制劑

Info

Publication number
HK1222647A1
HK1222647A1 HK16110755.6A HK16110755A HK1222647A1 HK 1222647 A1 HK1222647 A1 HK 1222647A1 HK 16110755 A HK16110755 A HK 16110755A HK 1222647 A1 HK1222647 A1 HK 1222647A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
HK16110755.6A
Other languages
English (en)
Inventor
．萬尼爾
．雷
．阿爾卡拉斯
．潘查爾
．詹寧斯
．阿瑪尼
．克裡蒂蘭德
．赫爾利
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47471708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1222647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of HK1222647A1 publication Critical patent/HK1222647A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16110755.6A 2011-12-09 2015-02-06 激酶抑制劑 HK1222647A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11192871 2011-12-09
EP12187931 2012-10-10

Publications (1)

Publication Number Publication Date
HK1222647A1 true HK1222647A1 (zh) 2017-07-07

Family

ID=47471708

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16110755.6A HK1222647A1 (zh) 2011-12-09 2015-02-06 激酶抑制劑
HK15101368.5A HK1200828A1 (zh) 2011-12-09 2015-02-06 激酶抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15101368.5A HK1200828A1 (zh) 2011-12-09 2015-02-06 激酶抑制劑

Country Status (35)

Country Link
US (5) US8907094B2 (zh)
EP (1) EP2788349B1 (zh)
JP (1) JP6128449B2 (zh)
KR (1) KR101994381B1 (zh)
CN (3) CN105968110B (zh)
AR (1) AR089189A1 (zh)
AU (1) AU2012347350C1 (zh)
BR (1) BR112014013760A2 (zh)
CA (1) CA2858447C (zh)
CL (1) CL2014001486A1 (zh)
CO (1) CO6970602A2 (zh)
CY (1) CY1118340T1 (zh)
DK (1) DK2788349T3 (zh)
EA (1) EA025268B1 (zh)
ES (1) ES2612259T3 (zh)
GE (1) GEP201706735B (zh)
HK (2) HK1222647A1 (zh)
HR (1) HRP20161714T1 (zh)
HU (1) HUE029826T2 (zh)
IL (1) IL232958A (zh)
LT (1) LT2788349T (zh)
ME (1) ME02624B (zh)
MX (1) MX359200B (zh)
MY (1) MY170656A (zh)
PE (1) PE20141370A1 (zh)
PH (1) PH12014501277A1 (zh)
PL (1) PL2788349T3 (zh)
PT (1) PT2788349T (zh)
RS (1) RS55602B1 (zh)
SG (1) SG11201402985VA (zh)
SI (1) SI2788349T1 (zh)
TW (1) TWI618703B (zh)
UA (1) UA115320C2 (zh)
WO (1) WO2013083604A1 (zh)
ZA (1) ZA201404156B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458154B2 (en) * 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2013083606A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
ES2612259T3 (es) * 2011-12-09 2017-05-16 Chiesi Farmaceutici S.P.A. Inhibidores de cinasa
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
US9732063B2 (en) 2012-11-16 2017-08-15 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
TWI641592B (zh) 2013-04-02 2018-11-21 英商瑞斯比維特有限公司 激酶抑制劑
EP2981534B1 (en) 2013-04-02 2017-07-19 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
US9359354B2 (en) * 2013-06-06 2016-06-07 Chiesi Farmaceutici S.P.A. Kinase inhibitors
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
KR20160016973A (ko) 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2014369449B2 (en) 2013-12-20 2018-07-05 Oxular Acquisitions Limited Urea derivatives useful as kinase inhibitors
KR102413704B1 (ko) 2014-02-14 2022-06-24 레스피버트 리미티드 항염증성 화합물로서의 방향족 헤테로사이클릭 화합물
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
BR112018067552A2 (pt) 2016-04-06 2019-01-08 Topivert Pharma Ltd inibidores de cinase
US10364245B2 (en) * 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺
AR116628A1 (es) 2018-10-18 2021-05-26 Syngenta Crop Protection Ag Compuestos microbiocidas
KR20220151177A (ko) 2020-03-05 2022-11-14 신젠타 크롭 프로텍션 아게 살진균 조성물
CN112174870B (zh) * 2020-10-12 2023-07-21 蔡霈 (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
EP1381592A1 (en) * 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused compounds
WO2003053930A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
US6872726B2 (en) * 2002-08-08 2005-03-29 Boehringer Ingelheim Pharmaceuticals Inc. Fluorinated di-aryl urea compounds
DE602004001676T2 (de) * 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
GEP20104973B (en) 2004-08-12 2010-04-26 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MX2007001612A (es) 2004-08-18 2007-04-10 Upjohn Co Compuestos novedosos de triazolopiridina para el tratamiento de la inflamacion.
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JP2008545756A (ja) 2005-06-03 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌化学療法剤として有用な１−メチル−１ｈ−ピラゾール−４−カルボキサミド類
WO2007091152A1 (en) * 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
CN101146029B (zh) * 2006-09-13 2011-12-28 华为技术有限公司 一种分组重排序方法和系统
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
CN101636397B (zh) 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途
WO2009015000A1 (en) 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
US20110207729A1 (en) 2007-08-10 2011-08-25 Astellas Pharma Inc. Bicyclic acylguanidine derivative
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
WO2010067131A1 (en) * 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
EP2384320B1 (en) 2009-01-05 2015-03-04 Boehringer Ingelheim International GmbH Pyrrolidine compounds which modulate the cb2 receptor
PE20120655A1 (es) 2009-02-17 2012-06-07 Chiesi Farma Spa Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US8721380B2 (en) 2009-08-12 2014-05-13 Konica Minolta Holdings, Inc. Method for manufacturing display panel
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) * 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
ES2612259T3 (es) 2011-12-09 2017-05-16 Chiesi Farmaceutici S.P.A. Inhibidores de cinasa
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
US9359354B2 (en) 2013-06-06 2016-06-07 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR20160016973A (ko) 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체

Also Published As

Publication number Publication date
BR112014013760A2 (pt) 2017-06-13
US9145413B2 (en) 2015-09-29
US20150344475A1 (en) 2015-12-03
HRP20161714T1 (hr) 2017-02-10
CY1118340T1 (el) 2017-06-28
IL232958A0 (en) 2014-08-03
SI2788349T1 (sl) 2017-01-31
US9527846B2 (en) 2016-12-27
PH12014501277B1 (en) 2014-09-08
UA115320C2 (uk) 2017-10-25
US9139584B2 (en) 2015-09-22
RS55602B1 (sr) 2017-06-30
CN104039787B (zh) 2016-06-29
DK2788349T3 (en) 2017-01-30
TWI618703B (zh) 2018-03-21
JP6128449B2 (ja) 2017-05-17
PE20141370A1 (es) 2014-10-17
US20160229852A1 (en) 2016-08-11
MX359200B (es) 2018-09-19
CL2014001486A1 (es) 2014-11-14
US20130150343A1 (en) 2013-06-13
TW201336833A (zh) 2013-09-16
PH12014501277A1 (en) 2014-09-08
CN105968110A (zh) 2016-09-28
AR089189A1 (es) 2014-08-06
KR101994381B1 (ko) 2019-06-28
ZA201404156B (en) 2016-07-27
CA2858447C (en) 2020-10-27
AU2012347350B2 (en) 2016-09-08
PT2788349T (pt) 2017-02-02
EA025268B1 (ru) 2016-12-30
CO6970602A2 (es) 2014-06-13
MX2014006724A (es) 2014-08-29
EP2788349B1 (en) 2016-10-26
WO2013083604A1 (en) 2013-06-13
SG11201402985VA (en) 2014-08-28
US20150080375A1 (en) 2015-03-19
HUE029826T2 (en) 2017-04-28
US20140323470A1 (en) 2014-10-30
KR20140105516A (ko) 2014-09-01
HK1200828A1 (zh) 2015-08-14
LT2788349T (lt) 2016-12-27
NZ625965A (en) 2016-08-26
EP2788349A1 (en) 2014-10-15
CA2858447A1 (en) 2013-06-13
GEP201706735B (en) 2017-09-25
IL232958A (en) 2017-08-31
US9315503B2 (en) 2016-04-19
AU2012347350C1 (en) 2017-01-19
AU2012347350A1 (en) 2014-07-03
ES2612259T3 (es) 2017-05-16
ME02624B (me) 2017-06-20
EA201490949A1 (ru) 2014-11-28
CN105503861B (zh) 2017-08-01
CN105503861A (zh) 2016-04-20
PL2788349T3 (pl) 2017-04-28
US8907094B2 (en) 2014-12-09
MY170656A (en) 2019-08-24
CN104039787A (zh) 2014-09-10
CN105968110B (zh) 2018-04-27
JP2015500260A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
HK1200828A1 (zh) 激酶抑制劑
HUE048834T2 (hu) Kináz inhibitorok
HK1200451A1 (zh) 蛋白激酶抑制劑
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SI2710005T1 (sl) Zaviralci tirozinske kinaze
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL229028A0 (en) Kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1199873A1 (zh) 激酶抑制劑
GB201009731D0 (en) Kinase inhibitors
ZA201306855B (en) Protein kinase inhibitors
IL232234A0 (en) Inhibitors of aminopyrimidine kinase
IL228928A0 (en) Aminopyrimidine kinase inhibitors
GB201120474D0 (en) Inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211204